30 Aug 2016  |  Global
This Vital Signs issue discusses the clinical diagnostics laboratory tests payment system, approval of a Zika test kit, the impact on innovation of mergers in the pharma/biotech industry, and national healthcare expenditure projections through 2025.
Special Price $450.00 save 25 %
02 Aug 2016  |  Global
This Vital Signs issue discusses Luminex's acquisition of Nanosphere, Medicare's changing approach to paying doctors, Orig3N's partnership with the San Francisco 49ers for collection of blood samples for research, and FDA's halt of Juno Therapeuticss cell therapy trial which left three dead.
30 Jun 2016  |  Global
This Vital Signs issue discusses Sinocare's acquisition of PTS Diagnostics, biosimilar drug pricing, Americans' usage of prescription pain killers, and Takara Bio's acquistion of Wafergen Bio-systems.
24 May 2016  |  Global
This Vital Signs issues trends in orphan drugs, genetic research apps, Thermo Fisher Scientific's acquisition of Affymetrix, and the Zika Virus.
04 Apr 2016  |  Global
Exciting Developments in Generic Drug Pricing, CRISPR Technology, GenomeAsia 100K and Large-scale Next-generation Sequencing Projects, and Medicare Outcomes
This Vital Signs issues discusses generic drug pricing, CRISPR technology, GenomeAsia 100K and large-scale next-generation sequencing projects, and Medicare outcomes target.
18 Mar 2016  |  North America
Additional Clinical Trials Critical to Building on Early Promise
As indicated by the World Health Organization, stroke is the second-leading cause of death for people over the age of 60 and is the fifth-leading cause of death for those between the ages of 15 and 59. The incidence of stroke is expected to increase by 25% over the next 20 years. Over 40% of ischemic stroke victims have permanent symptoms and only ...
18 Mar 2016  |  North America
Modified Swine Hold out Promise of Improving Pre-Clinical Efficacy, Lowering Multi-billion Dollar Drug and Device Development Costs
The US pharmaceutical industry spends approximately $100 billion annually to develop new pharmaceutical drugs and medical devices. Today, a new drug takes approximately 15 years and over $1 billion to bring to market. Product development costs could be greatly reduced by using animal models that more closely resemble humans in their disease states ...
12 Feb 2016  |  Global
Portfolio Expansions Follow Acquisitions by Panasonic Healthcare Holdings Co.,Thermo Fisher Scientific and Abbott Laboratories
This Vital Signs issues discusses Panasonic Healthcare's completed acquisition of Bayer's Diabetes Care Unit, Thermo Fisher Scientific's acquisition of Affymetrix, several moves in the single cell-genomics market by Bio-Rad, Illumina, Qiagen, and 10x Genomics, and Abbott's acquisition of Alere.
10 Feb 2016  |  North America
Vital Signs - Technology Developments in Medical Imaging Markets, Radiological Society of North America (RSNA) Meeting 2015
Medical 3D Printing and Medical Imaging Equipment Asset Management Services, Advanced Enterprise Imaging Informatics Seek to Capture Growth Opportunities
\ Frost & Sullivan attended the annual meeting of the Radiological society of North America (RSNA). The four themes we have developed in our coverage of the 2015 edition fall under the topic areas of:\ I- Competitive Landscape and New Business Models, looking at new entrants in the capital imaging equipment arena, the recent developments in techn...
Special Price $562.50 save 25 %
04 Feb 2016  |  Global
Vital Signs - Spiraling US Drug Costs, Wearable Healthcare Technologies and the Zika Virus, An Analysis
Urgent Remedial Action Required as Nearly 1/4th US Prescription Drug Users Find it Difficult to Afford their Prescriptions
This issue of Vital Signs discusses why the US pays more than other countries for drugs, the inside story on wearable electronics, the spreading Zika virus, and soaring US drug costs.